Pelthos Therapeutics Inc. (PTHS)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Pelthos Therapeutics Inc. (PTHS) is listed on NYSE American, where it has traded since February 16, 2024.
- Listed On
- NYSE American
- Listed Since
- February 16, 2024
- Employees
- 92
- Market Cap
- $78M
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 23 institutions reported holding PTHS, with 1.3 million shares worth $37.4 million in aggregate. The largest reported holder was Aigh Capital Management, with 329,098 shares worth $9.3 million. Of the 5 largest holders listed below, 1 opened a new position in PTHS, 3 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Aigh Capital Management | 329,098 | $9M | New position |
| Murchinson Ltd | 304,302 | $9M | Added 2.7% |
| Ikarian Capital | 256,598 | $7M | Unchanged |
| Vanguard | 107,007 | $3M | Added 3.98% |
| Boothbay Fund Management | 101,976 | $3M | Added 24.58% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PTHS?
Pelthos Therapeutics Inc. (PTHS) is listed on NYSE American, where it has traded since February 16, 2024.
Who are the largest institutional holders of PTHS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PTHS were Aigh Capital Management, Murchinson Ltd and Ikarian Capital.
How many institutions own PTHS?
23 institutions reported a position in PTHS for the quarter ended June 30, 2026, worth $37.4 million in total.
Did institutions buy or sell PTHS last quarter?
Of the 5 largest reported holders, 1 opened a new position in PTHS, 3 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PTHS.
Every reported institutional holder, plus insider and congressional trades in PTHS, on SentiSense.